News | December 05, 2025
Lupin inks US licensing deal with Valorum for biosimilar Armlupeg
Valorum will advance the commercialization and distribution of Armlupeg in the United States
Valorum will advance the commercialization and distribution of Armlupeg in the United States
Health Canada’s approval was based on a comprehensive evaluation of analytical, nonclinical, and clinical data
The platform integrates with CT imaging and uses deep learning models to generate a 3D digital twin of lung anatomy
The deal aims to address long-standing imbalances in pharmaceutical trade while boosting investment and innovation on both sides of the Atlantic
Ilumya is the first IL-23 inhibitor to complete five years of study based on a pooled analysis of two Phase 3 efficacy and safety extension trials
Armlupeg is indicated for decrease the incidence of infection, as manifested by febrile neutropenia, in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs
GLP-1 therapies are among the fastest-growing drug classes worldwide, projected to drive a $95 billion obesity market by 2030
India's pharmaceutical sector is rapidly shifting from a generics-led foundation to an innovation-driven ecosystem
The new Bioprocess Design Center will serve as a cutting-edge scale-up hub for biologics and vaccine manufacturing
Subscribe To Our Newsletter & Stay Updated
